Grass Pollen Allergen Extract Modified With Glutaraldehyde And Adsorbed To L-Tyrosine

This article discusses clinical trials investigating the use of Grass Pollen Allergen Extract Modified With Glutaraldehyde And Adsorbed To L-Tyrosine (PQ Grass) for treating seasonal allergic rhinitis in children and adolescents. The trials aim to evaluate the efficacy, safety, and long-term effects of this treatment for grass pollen-induced allergies.

Related diseases and areas:

• Conjunctivitis allergic

Gremubamab

A new clinical trial is underway to evaluate the effectiveness of Gremubamab, a potential treatment for patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. This phase 2 trial aims to compare Gremubamab with a placebo to assess its impact on bacterial burden, quality of life, and lung function in affected individuals. The study, known as the GRemubamab ErAdication Trial (GREAT-2), offers hope for those struggling with this challenging respiratory condition.

Related diseases and areas:

• Pulmonary tuberculosis
• Bronchiectasis

GRISNILIMAB SETARITOX

Clinical trials investigating GRISNILIMAB SETARITOX are studying its use in early diffuse cutaneous systemic sclerosis, a serious form of autoimmune disease that affects the skin and sometimes internal organs. The trial data focus on safety in a small group of patients and measure harmful events during and after treatment.

Related diseases and areas:

• Systemic scleroderma

GRNA-001

Clinical trials are investigating GRNA-001 in people with Primary Hyperoxaluria Type 1 (PH1). The study is looking at safety and tolerability, and it is in an early phase trial with 23 participants. This article explains what the trial is studying and who it is for.

Related diseases and areas:

• Primary hyperoxaluria

GRNA1599

Clinical trials are investigating GRNA1599 in people with chronic hepatitis B. The study is looking at safety, tolerability, and early signs of effect in adults with this long-term liver infection. It is also checking how the study drug behaves in the body and whether it may help control the disease.

Related diseases and areas:

• Chronic hepatitis B

GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197

Clinical trials are studying GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197 in healthy pregnant women and their infants. These trials mainly look at safety, tolerability, and whether the vaccine can help protect babies from group B streptococcal disease.

Grwd5769

GRWD5769 is an innovative drug currently being studied in clinical trials for patients with advanced solid tumors. This article provides an overview of the ongoing research, focusing on the safety, tolerability, and potential effectiveness of GRWD5769 when used alone or in combination with other cancer treatments. The trials aim to determine the optimal dosage and evaluate the drug’s impact on various types of solid malignancies, offering hope for patients with limited treatment options.

Related diseases and areas:

• Neoplasm malignant

Gs-1427

Clinical trials are studying Gs-1427 in people with moderately to severely active ulcerative colitis. These trials are designed to check whether Gs-1427 can help improve symptoms and measure its safety and effectiveness compared with placebo.

Related diseases and areas:

• Colitis ulcerative

GS-1720

Clinical trials are studying GS-1720 in people with HIV-1 infection. These studies look at how well GS-1720 works, how safe it is, and how it compares with Biktarvy in people who have not been treated and in people whose HIV is already controlled.

Related diseases and areas:

• HIV infection

GS-248

Clinical trials are investigating GS-248 in women with endometriosis. These studies aim to evaluate treatment benefit and safety, especially for endometriosis-related pain. The available trial data describes a Phase 2 study comparing GS-248 with placebo in adult women.

Gs-4182

Clinical trials are studying Gs-4182 in people with HIV-1 infection. These studies look at how well Gs-4182 works in weekly oral regimens compared with Biktarvy, and they measure virologic suppression in both people who are already suppressed and people who have not been treated before.

Related diseases and areas:

• HIV infection

GS-4321

Clinical trials are studying GS-4321 in healthy participants and in people with chronic hepatitis delta virus infection. These trials are looking at safety, tolerability, how the body handles GS-4321, and early signs of benefit in hepatitis delta. The study includes Phase 1/2 testing in both healthy volunteers and patients with chronic hepatitis delta.

Gs-5245

Obeldesivir, also known as GS-5245, is an investigational drug being studied for the treatment of COVID-19. This article summarizes key information from clinical trials evaluating Obeldesivir in different patient populations, including children, adolescents, and adults with varying levels of kidney function. The trials aim to assess the safety, effectiveness, and how the body processes this potential new treatment for COVID-19.

Related diseases and areas:

• Renal impairment
• COVID-19

Gs-5718-03

A clinical trial is underway to assess the effectiveness, safety, and tolerability of GS-5718-03, a new drug being tested for patients with Cutaneous Lupus Erythematosus (CLE). This randomized, blinded, placebo-controlled study aims to explore the potential of GS-5718-03 in reducing skin disease activity in CLE patients, with or without Systemic Lupus Erythematosus (SLE). The trial will evaluate various aspects of the drug’s performance, including its efficacy, safety profile, and pharmacokinetic characteristics.

Related diseases and areas:

• Cutaneous lupus erythematosus

Gsk3739937

Clinical trials are investigating Gsk3739937 in adults with HIV-1 infection. The study looks at antiviral activity, safety-related outcomes, and changes in plasma HIV-1 RNA in treatment-naive participants. It is a Phase 2 trial in a small group of adults.

Related diseases and areas:

• HIV infection

Gsk3858279

Clinical trials are studying Gsk3858279 in people with pain from diabetic peripheral neuropathic pain and knee osteoarthritis. These studies are looking at whether it can reduce pain and how safe it is in adults. Both trials are phase 2 studies and have already been completed.

Related diseases and areas:

• Diabetic neuropathy
• Osteoarthritis

GSK3862995B

Clinical trials are investigating GSK3862995B in people with bronchiectasis. These studies look at how well it works, how safe it is, and how the body handles repeat doses. The main trial is in adults 18 to 85 years old with recurrent exacerbations or uncontrolled symptoms.

Related diseases and areas:

• Bronchiectasis

Gsk3915393

Clinical trials are investigating Gsk3915393 in people with idiopathic pulmonary fibrosis (IPF), a long-term lung disease that causes scarring. These studies aim to evaluate how well Gsk3915393 works and how safe it is, mainly in adults with IPF. The main trial listed is a phase 2 study comparing Gsk3915393 with placebo.

Related diseases and areas:

• Idiopathic pulmonary fibrosis

Gsk3965193B

This article discusses the ongoing clinical trials of GSK3965193B, a promising drug being studied for the treatment of chronic hepatitis B infection. The trials aim to assess the safety, tolerability, and effectiveness of GSK3965193B when used alone and in combination with another drug called bepirovirsen. These studies involve both healthy participants and those living with chronic hepatitis B, focusing on how the drug affects the body and its potential to combat the hepatitis B virus.

Related diseases and areas:

• Chronic hepatitis B

Gsk4004280

This article discusses a clinical trial investigating the use of GSK4004280, a new oral capsid inhibitor, in the treatment of HIV-1 infections. The study aims to assess the drug’s antiviral effects, safety, tolerability, and pharmacokinetics in treatment-naïve adults with HIV-1. This research is an important step in developing new therapeutic options for people living with HIV.

Related diseases and areas:

• HIV infection

Gsk4011499

This article discusses a clinical trial investigating the use of GSK4011499, a novel capsid inhibitor, in the treatment of HIV-1 infection. The study aims to assess the drug’s antiviral effects, safety, tolerability, and pharmacokinetics in treatment-naïve adults with HIV-1. This research is an important step in developing new therapies for HIV-1 and potentially improving treatment options for patients.

Related diseases and areas:

• HIV infection

Gsk4381562A

This article discusses the clinical trial of GSK4381562A, a promising drug being studied in combination with other immunotherapies for the treatment of recurrent or metastatic head and neck cancer. The trial aims to evaluate the effectiveness and safety of this new approach compared to existing treatments for patients with PD-L1 positive tumors.

Related diseases and areas:

• Squamous cell carcinoma of …

GSK4418959A

Clinical trials are studying GSK4418959A in people with dMMR/MSI-H solid tumors, including colorectal cancer. The trials are looking at safety, tolerability, dose selection, and early signs of anti-tumor activity. Some parts test GSK4418959A alone, and others test it with a PD-1 inhibitor.

Related diseases and areas:

• Colorectal cancer
• Microsatellite instability …

GSK4524101A

Clinical trials are studying GSK4524101A in adults with advanced or metastatic solid tumors, and in a breast cancer expansion group. The research looks at safety, tolerability, how the body handles the treatment, and early signs of anticancer activity, both alone and with niraparib.

Related diseases and areas:

• Neoplasm
• Breast cancer metastatic

Gsk4527226

Clinical trials of Gsk4527226 are studying people with early Alzheimer’s disease. These studies look at both safety and how well the treatment may work over time. The trials include a main treatment study and an open-label extension, which follows participants longer after the parent study.

Related diseases and areas:

• Dementia Alzheimer’s type

Gsk4532990A

GSK4532990A is being studied in clinical trials for its potential to treat liver diseases, specifically nonalcoholic steatohepatitis (NASH) and alcohol-related liver disease (ALD). These trials aim to assess the drug’s safety, effectiveness, and optimal dosing in patients with various stages of liver fibrosis and impairment. The studies focus on important markers of liver health and disease progression, offering hope for patients with these challenging conditions.

Related diseases and areas:

• Metabolic dysfunction-assoc…

GSK5458514

Clinical trials are studying GSK5458514 in men with metastatic castration-resistant prostate cancer (mCRPC). These studies aim to assess safety, tolerability, and the highest dose that can be given, alone or with other anti-cancer agents. The trial is in Phase 1/2 and includes adults with prostate cancer.

Related diseases and areas:

• Hormone-refractory prostate…

GSK5460025A

Clinical trials are investigating GSK5460025A in people with dMMR/MSI-H solid tumors, including colorectal cancer. These studies aim to check safety, tolerability, dose, and early signs of anti-cancer activity, both alone and with other cancer treatments. The trial includes adults with specific solid tumors, and one part also looks at colorectal and endometrial cancer.

GSK5733584

Clinical trials are investigating GSK5733584 in people with advanced solid tumors, including gynecological cancers. These studies look at safety, tolerability, and early anticancer activity when GSK5733584 is used with other cancer treatments.

Related diseases and areas:

• Neoplasm

GSK5764227

Clinical trials are studying GSK5764227 in people with advanced cancers, including gastrointestinal tumors, relapsed small cell lung cancer, and other solid tumors. These studies are checking safety, tolerability, and signs of anti-cancer activity in different patient groups and trial phases.

Related diseases and areas:

• Gastrointestinal cancer met…
• Small cell lung cancer
• Neoplasm
• Amyloidosis

GSK5784283

Clinical trials are studying GSK5784283 in adults with uncontrolled asthma. These studies aim to find the right dose and measure effects on airway inflammation and asthma control. The main trial listed here compares GSK5784283 with placebo in adults aged 18 to 75 years.

Related diseases and areas:

• Asthma

Gsk6097608

Clinical trials are studying Gsk6097608 in people with certain advanced cancers. These trials look at safety and how well Gsk6097608 works in combination with other immunotherapy drugs in first-line treatment for non-small cell lung cancer and head and neck cancer.

Related diseases and areas:

• Squamous cell carcinoma of …
• Non-small cell lung cancer

Gskvx000000008866

This article discusses clinical trials investigating the use of GSKVx000000008866, a novel drug candidate, for the treatment of chronic hepatitis B (CHB). These trials aim to assess the safety, efficacy, and immune response of GSKVx000000008866 alone or in combination with other therapies in patients with CHB who are already on nucleos(t)ide analogue (NA) therapy. The studies explore different dosing regimens and administration methods to determine the most effective approach for managing this persistent viral infection.

Related diseases and areas:

• Chronic hepatitis B

Gskvx000000008885

Clinical trials are underway to evaluate the safety, efficacy, and immune response of GSKVX000000008885, a novel therapeutic vaccine for chronic hepatitis B (CHB). This vaccine is being tested in combination with other treatments in patients who are already on nucleos(t)ide analogue (NA) therapy. The trials aim to assess the potential of this vaccine to improve outcomes for CHB patients by targeting the hepatitis B virus (HBV) and boosting the immune response against it.

Related diseases and areas:

• Chronic hepatitis B

Gskvx000000009151

This article discusses clinical trials investigating the use of GSKVX000000009151, a novel therapeutic vaccine, for the treatment of chronic hepatitis B (CHB). The trials aim to evaluate the safety, efficacy, and immune response of this vaccine in combination with other treatments in patients with CHB who are already on nucleos(t)ide analogue (NA) therapy.

Related diseases and areas:

• Chronic hepatitis B

Gskvx000000014593

This article discusses the clinical trials of GSK’s Herpes Zoster vaccine, known as GSKVx000000014593, in immunocompromised children aged 1-17 who have received kidney transplants. The study aims to assess the safety, reactogenicity, and immune response of this vaccine in this specific patient population. The trials are designed to evaluate the vaccine’s potential in preventing Herpes Zoster (shingles) in these vulnerable children.

Related diseases and areas:

• Herpes zoster

Gskvx000000017033

This article discusses clinical trials investigating the use of GSKVx000000017033, a novel drug candidate, for the treatment of chronic hepatitis B. The trials aim to assess the safety, efficacy, and immune response of this drug when used alone or in combination with other therapies in patients with chronic hepatitis B who are already on nucleos(t)ide analogue therapy.

Related diseases and areas:

• Chronic hepatitis B

GSKVX000000017986

Clinical trials are studying GSKVX000000017986 as part of meningococcal vaccine research. These studies look at safety, side effects after vaccination, and immune response in healthy participants. The trial data here focuses on different vaccine formulations and comparisons with other vaccines.

Related diseases and areas:

• Meningococcal infection

GSKVX000000025896

Clinical trials are investigating GSKVX000000025896 in healthy children, mainly to study a chickenpox (varicella) vaccine. These studies look at immune response, safety, and how the vaccine performs compared with marketed vaccines in children aged 12 to 15 months and 4 to 6 years.

Related diseases and areas:

• Varicella
• Varicella zoster virus infe…
• Rubella
• Measles

GSKVX000000030810

Clinical trials are investigating GSKVX000000030810 in people with herpes simplex, including healthy adults and adults with recurrent genital herpes. These studies look at safety, local and whole-body reactions, immune response, and whether the study treatment can reduce herpes episodes. The trials are in Phase 1/2.

Related diseases and areas:

• Genital herpes

GSKVX000000030825

Clinical trials are studying GSKVX000000030825 in people with herpes simplex and in healthy adults. These studies look at safety, side effects after each dose, immune response, and whether the treatment can help prevent recurrent genital herpes. The trials include healthy participants aged 18-40 years and participants aged 18-60 years with recurrent genital herpes.

Related diseases and areas:

• Genital herpes

GSKVX000000030918

Clinical trials are studying GSKVX000000030918 in people with herpes simplex. These studies look at safety, side effects, immune response, and whether the treatment can help prevent recurrent genital herpes. The trials include healthy adults and adults with recurrent genital herpes.

Related diseases and areas:

• Genital herpes

GSKVX000000034792

Clinical trials are studying GSKVX000000034792 in healthy younger and older adults to find and confirm a dose and to assess safety, reactogenicity, and immune response. The trial also compares immune responses after vaccination. These studies help researchers understand how the vaccine performs in prevention of influenza infection.

Related diseases and areas:

• Influenza

GSKVX000000034794

Clinical trials are investigating GSKVX000000034794 in influenza vaccine studies. These trials look at immune response, safety, and reactogenicity in healthy adults and adults 18 years and older. The studies compare different vaccine versions and measure how well they work and how well they are tolerated.

Related diseases and areas:

• Influenza

GSKVX000000034795

Clinical trials are investigating GSKVX000000034795 as part of influenza vaccine research in healthy younger and older adults. These studies look at safety, reactogenicity, and immune response, including dose finding and confirmation. The main goal is to see how well the vaccine works in people who do not have influenza infection.

Related diseases and areas:

• Influenza

GSKVX000000034796

Clinical trials are investigating GSKVX000000034796 as part of influenza vaccine research in healthy younger and older adults. These studies aim to find and confirm the dose and assess safety, reactogenicity, and immune response. The target population is healthy volunteers taking part in prevention studies for influenza infection.

Related diseases and areas:

• Plasma cell myeloma
• Influenza

GSKVX000000034797

Clinical trials are investigating GSKVX000000034797 as part of an influenza vaccine study in healthy younger and older adults. The trial is looking at safety, reactogenicity, and immune response, and it compares study vaccine groups with licensed flu vaccines.

Related diseases and areas:

• Influenza

GSKVX000000034798

Clinical trials are investigating GSKVX000000034798 as part of influenza vaccine studies in healthy adults and adults 18 years and older. These trials look at safety, reactogenicity, and immune response, with some also comparing GSKVX000000034798 to other influenza vaccines. The studies include Phase 1/2 and Phase 2 research.

Related diseases and areas:

• Influenza

GSKVX000000039711

Clinical trials are investigating GSKVX000000039711 as part of an influenza vaccine study in healthy younger and older adults. The trials aim to assess safety, reactogenicity, and immune response, including dose finding and confirmation.

Related diseases and areas:

• Influenza

GSKVX000000040033

Clinical trials are investigating GSKVX000000040033 as part of an influenza vaccine study in healthy younger and older adults. The trials aim to find and confirm the dose, and to assess safety, reactogenicity, and immune response. They include healthy volunteers and are designed to compare different vaccine options.

Related diseases and areas:

• Influenza

GSKVX000000044501

Clinical trials are investigating GSKVX000000044501 in a candidate vaccine study for urinary tract infections. These trials look at safety, immune response, and whether it can help prevent new E. coli UTIs in adults, especially females aged 18 to 64 years.

Related diseases and areas:

• Urinary tract infection

GSKVX000000046019

Clinical trials are investigating GSKVX000000046019 as a candidate vaccine for urinary tract infections (UTIs). The studies aim to check safety, immune response, and whether it can help prevent new E. coli UTIs in adults, especially females aged 18 to 64 years.

Related diseases and areas:

• Urinary tract infection

GSKVX000000048110

Clinical trials investigating GSKVX000000048110 are studying influenza vaccines in adults, including healthy younger and older adults and adults 18 years and older. These trials look at immune response, safety, and reactogenicity, which means how often side effects happen after vaccination. The studies are in Phase 1/2 and Phase 2.

Related diseases and areas:

• Influenza
• Tonsillitis

GSKVX000000048111

Clinical trials are investigating GSKVX000000048111 in studies of influenza vaccines for adults and healthy volunteers. These trials look at immune response, safety, and reactogenicity, which means how often short-term side effects happen after vaccination. The studies include Phase 1/2 and Phase 2 trials in adults 18 years and older.

Related diseases and areas:

• Influenza
• Tonsillitis

GSKVX000000070248

Clinical trials are investigating GSKVX000000070248 as part of influenza vaccine studies in adults 18 years and older. These trials look at immune response, safety, and reactogenicity, which means how often short-term reactions happen after vaccination. They compare different study vaccine groups and other influenza vaccines.

GSKVX000000070250

Clinical trials are studying GSKVX000000070250 in adults 18 years and older with influenza-related vaccination research. These studies look at immune response, safety, and reactogenicity, which means how often short-term reactions happen after vaccination.

GSKVX000000070965

Clinical trials are studying GSKVX000000070965 in adults 18 years and older. These trials aim to measure immune response, safety, and reactogenicity, which means how often short-term side effects happen after vaccination. The study is for people with influenza, human.

Gt005

Clinical trials are investigating Gt005 in people with geographic atrophy, a form of vision loss linked to age-related macular degeneration. The study data focus on long-term safety, especially in participants who already received Gt005 in earlier Gyroscope studies. The main goal is to see how safe the treatment is over time.

Related diseases and areas:

• Dry age-related macular deg…

Gtaexs617

Clinical trials are investigating Gtaexs617 in people with advanced solid tumors. This article explains what the study is trying to learn, including safety, tolerability, and early anti-tumor activity. It also covers the study phase, who may take part, and the main outcomes being measured.

Related diseases and areas:

• Adenocarcinoma pancreas
• Colorectal adenocarcinoma
• Ovarian epithelial cancer
• Squamous cell carcinoma of …
• Non-small cell lung cancer
• Breast cancer